AIP
PROF

ARS Investment Partners’s Profound Medical PROF Stock Holding History

ARS Investment Partners’s Portfolio PROF Stock Details PROF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$164K – 171
2021
Q2 		$164K Hold
10,000
– – 0.02% 138
2021
Q1 		$201K Hold
10,000
– – 0.02% 132
2020
Q4 		$206K Buy
+10,000
New +$184K 0.03% 116

Other funds holding PROF

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BC
Blackcrane Capital Bellevue, Washington $16.3M AUM 19.53% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GA
Gagnon Advisors New York $136M AUM 21.55% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

ARS Investment Partners's PROF Position: Q3 2021 in Review

ARS Investment Partners sold out of Profound Medical (PROF) in Q3 2021, closing a stake of 10,000 shares — an estimated $164K sold.

ARS Investment Partners first reported a position in PROF in Q4 2020 and held it in 3 quarters. The position peaked at $206K in Q4 2020. 46 funds tracked by Wall St. Rank hold PROF as of Q3 2021.

  • ARS Investment Partners reported no remaining Profound Medical position as of Q3 2021 after selling out during the quarter.
  • ARS Investment Partners sold 10,000 Profound Medical shares in Q3 2021, an estimated $164K.
  • ARS Investment Partners first reported a position in Profound Medical in Q4 2020 and held it in 3 quarters.
  • ARS Investment Partners's Profound Medical position peaked at $206K in Q4 2020.
  • 46 funds tracked by Wall St. Rank held Profound Medical as of Q3 2021.

Based on ARS Investment Partners's 13F filing for Q3 2021, filed 5 Nov 2021.